Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
44 NC counties and 1 VA county are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Program
On WRAL at 6: Hundreds of millions overbudget, WRAL Investigates delays in a Medicaid upgrade costing taxpayers and impacting patients
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Prometheus Biosciences Inc
(NQ:
RXDX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 15, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Prometheus Biosciences Inc
< Previous
1
2
3
4
5
Next >
Why Shares of Exscientia Jumped on Wednesday
July 12, 2023
The company may be riding the wave of an AI healthcare boom.
Via
The Motley Fool
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
July 07, 2023
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as...
Via
Benzinga
Why Shares of Ventyx Biosciences Rose Monday
July 03, 2023
The company has several promising autoimmune therapies.
Via
The Motley Fool
Is Merck Stock a Top Buy Right Now?
June 19, 2023
The drugmaker is still a work in progress.
Via
The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
3 Innovative Growth Stocks to Buy for Next-Gen Profits
May 31, 2023
These are the innovative growth stocks for future profits as they represent companies investing significantly in research and development.
Via
InvestorPlace
RXDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Prometheus Biosciences, Inc. Is Fair to Shareholders
May 24, 2023
From
Halper Sadeh LLC
Via
Business Wire
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
May 22, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
3 Undervalued Pharma Stocks to Buy for High Total Returns
May 19, 2023
These are the undervalued pharma stocks to buy as they represent companies investing heavily in research to boost the product pipeline.
Via
InvestorPlace
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
May 16, 2023
In a rare move to block a large pharma deal, the U.S.
Via
Benzinga
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
May 16, 2023
Reports the FTC could block Amgen's takeover of Horizon reverberated across biotechs on Tuesday, with HZNP stock's crash leading the way.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
May 10, 2023
Via
Benzinga
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
May 09, 2023
- Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 -
From
Prometheus Biosciences
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)
May 03, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
May 01, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Here Are The Best-Performing Industry ETFs And Major Stock Contributors In April
April 30, 2023
It's a good time to look at how the major U.S. stock industry ETFs performed this month, as April comes to an end. In April, we saw the broader U.S.
Via
Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
April 28, 2023
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.
Via
Investor's Business Daily
Merck Makes a Bold Move That Could Transform Its Business
April 27, 2023
It's a risky deal for Merck, but it could pay off significantly.
Via
The Motley Fool
3 Biotechs That Might Get Bought Out in 2023
April 26, 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year.
Via
The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
April 25, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
This Supercharged Dividend King Stock Might Soon Run Out of Steam
April 25, 2023
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.
Via
The Motley Fool
PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
April 21, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review
April 21, 2023
The major indexes saw modest declines, holding in a range.
Via
Investor's Business Daily
Why Prometheus Biosciences Stock Is Skyrocketing This Week
April 20, 2023
There's nothing like a big buyout to send a clinical-stage biotech stock soaring higher.
Via
The Motley Fool
Why This Nasdaq Stock Caught Fire This Week
April 20, 2023
A wave of bargain buying benefited the gene therapy company's shares this week.
Via
The Motley Fool
Why Madrigal Pharmaceuticals Stock Gained 20% This Week
April 20, 2023
Two key tailwinds fueled a surge in the biotech's share price this week.
Via
The Motley Fool
Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?
April 19, 2023
Merck's move into immunology is a risky proposition.
Via
The Motley Fool
Why BELLUS Health Stock Is Rocketing Higher Today
April 18, 2023
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today.
Via
The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
April 18, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
April 18, 2023
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.